BIOCRYST PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.32 USD | -0.37% |
|
+19.55% | -11.19% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the BioCryst Q1 2...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Calendar
2024-05-13
- Citizens JMP Life Sciences Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
5.32
USD
Average target price
14
USD
Spread / Average Target
+163.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.19% | 1.1B | |
| +3.91% | 108B | |
| +10.87% | 104B | |
| +1.28% | 22.33B | |
| -13.14% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -10.66% | 17.64B | |
| +3.75% | 14.05B | |
| +36.70% | 12.51B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- Transcript : BioCryst Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 03, 2023
